Concurrent administration may result in elevated praziquantel plasma concentrations. In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. Therefore, use of praziquantel with bexarotene, a CYP3A4 inducer, should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. Therefore, use of praziquantel with felbamate, a CYP3A4 inducer, should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. You may need to break the tablet to get the correct dose. Mitotane is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate; coadministration may result in decreased plasma concentrations of praziquantel. [28515], 25 mg/kg/dose PO 3 times daily for 1 day; separate doses by 4 to 6 hours.[28515]. Biltricide® Praziquantel 600 mg Tablet Bottle 6 Tablets BILTRICIDE, TAB 600MG (6/BT) Features. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem fo… Not a Member? Generic name: PRAZIQUANTEL 600mgDosage form: tablet, film coated. If treatment with praziquantel is necessary, treatment with mitotane should be discontinued 4 weeks before administration of praziquantel. Phenytoin is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate; coadministration may result in decreased plasma concentrations of praziquantel. Last updated on Nov 9, 2020. In a crossover study with a 2-week washout period, administration of praziquantel followed by another strong CYP3A inducer resulted in undetectable plasma concentrations of praziquantel in 7 out of 10 subjects. Therefore, use of praziquantel with dabrafenib, a CYP3A4 inducer, should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. Ce médicament agit en tuant le parasite. In a crossover study with a 2-week washout period, administration of praziquantel followed by another strong CYP3A inducer resulted in undetectable plasma concentrations of praziquantel in 7 out of 10 subjects. Therefore, use of praziquantel with fosamprenavir, which is metabolized to a CYP3A4 inducer (amprenavir), should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. Apalutamide is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate. If treatment with praziquantel is necessary, treatment with enzalutamide should be discontinued 4 weeks before administration of praziquantel. Praziquantel further causes vacuolization and disintegration of the schistosome tegument. [28515], Published studies, including 2 randomized, controlled studies, have not identified a risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes with praziquantel use during human pregnancy. It is metabolized by the liver. [28515], Because parasite destruction within the eye may cause irreparable lesions, do not use praziquantel for ocular cysticercosis (retinal cysticercosis). Belladonna Alkaloids; Ergotamine; Phenobarbital: (Severe) The concomitant use of phenobarbital with praziquantel is contraindicated due to decreased exposure and efficacy of praziquantel. Fosphenytoin is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate; coadministration may result in decreased plasma concentrations of praziquantel. Primidone: (Severe) The concomitant use of primidone with praziquantel is contraindicated due to decreased exposure and efficacy of praziquantel. Therefore, use of praziquantel with etravirine, a CYP3A4 inducer, should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. The dose of this medicine will be different for different patients. If treatment with praziquantel is necessary, treatment with rifampin should be discontinued 4 weeks before administration of praziquantel. Nafcillin: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. DESCRIPTION. Treatment with phenobarbital can then be restarted 1 day after completion of praziquantel treatment. Data sources include IBM Watson Micromedex (updated 1 Apr 2021), Cerner Multum™ (updated 5 Apr 2021), ASHP (updated 6 Apr 2021) and others. Atropine; Hyoscyamine; Phenobarbital; Scopolamine: (Severe) The concomitant use of phenobarbital with praziquantel is contraindicated due to decreased exposure and efficacy of praziquantel. Primidone is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate. When praziquantel was administered two weeks after discontinuation of the strong inducer, the mean praziquantel AUC and Cmax were 23% and 35% lower, respectively, than when praziquantel was given alone. Rifampin is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate. St. John's Wort, Hypericum perforatum: (Severe) The concomitant use of St. John's Wort with praziquantel is contraindicated due to decreased exposure and efficacy of praziquantel. Your doctor will prescribe a dose specifically for you. Maximum Allowed Quantities for National Drug Code (NDC) Billing The allowed quantities in this section are calculated based upon both the maximum dosage information supplied within this policy as well as the process by which NDC claims are billed. The list below shows the daily dose for children based . All following dosages are for adults and children 4 or older. Press the score with the thumbnails. Bosentan: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. Armodafinil: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. For the treatment of paragonimiasis*: Oral dosage: Adults: 25 mg/kg/dose PO 3 times daily for 2 days. Fosamprenavir: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. Praziquantel is metabolized by the hepatic isoenzyme CYP3A4; ritonavir is an inhibitor of this enzyme. Treatment with rifampin can then be restarted 1 day after completion of praziquantel treatment. Therefore, use of praziquantel with efavirenz, a CYP3A4 inducer, should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. Children—Dose is based on body weight and must be determined by your doctor. Use caution, and monitor therapeutic effects of praziquantel when coadministered with vemurafenib. Children and Adolescents: 25 mg/kg/dose PO 3 times daily for 2 days. Praziquantel works by increasing the cell membrane permeability in susceptible worms. Treatment with phenobarbital can then be restarted 1 day after completion of praziquantel treatment. However, a higher 60 mg/kg single dose has also been used in some endemic countries as have been split doses on certain occasions. Lorlatinib is a moderate CYP3A4 inducer. Breast milk concentrations were undetectable 24 to 32 hours after exposure. BILTRICIDE® (praziquantel) is a trematodicide provided in tablet form for the oral treatment of schistosome infections and infections due to liver fluke Praziquantel can exacerbate CNS pathology due to schistosomiasis; avoid use in patients with a history of epilepsy (seizure disorder) and/or other signs of CNS involvement, such as subcutaneous nodules suggestive of cysticercosis. Etravirine: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. Dosage forms: TAB: 600 mg. schistosomiasis [20 mg/kg/dose PO tid x1 day] Info: separate doses by 4-6h; give w/ food; do not chew tab liver flukes [25 mg/kg/dose PO tid x1-2 days] Info: separate doses by 4-6h; give w/ food; do not chew tab *cysticercosis [50 mg/kg/day PO divided q8h x14 days] Info: give w/ food; do not chew tab *tapeworms Rifapentine: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. 25 mg/kg/day PO in varying regimens has been used with albendazole (varying regimens) with some efficacy. Treatment with phenytoin can then be restarted 1 day after completion of praziquantel treatment. Elagolix is a weak to moderate CYP3A4 inducer. Chloroquine: (Minor) Concomitant administration of chloroquine and praziquantel can reduce praziquantel bioavailability and maximum serum concentrations. Retreatment may be necessary for lesions persisting for 6 months after the end of therapy. Lesinurad; Allopurinol: (Moderate) Lesinurad may decrease the systemic exposure and therapeutic efficacy of praziquantel; monitor for potential reduction in efficacy. Biltricide Dosage. Clobazam: (Moderate) Use of praziquantel with clobazam should be done with caution as concomitant use may produce therapeutically ineffective concentrations of praziquantel. Segments are broken off by pressing the score (notch) with thumbnails. Lopinavir; Ritonavir: (Moderate) Monitor for increased side effects of praziquantel if administered with ritonavir. 25 mg/kg/dose PO 3 times daily for 2 days. Data have shown a potential lack of efficacy for praziquantel during the acute phase of schistosomiasis, with the drug not preventing progression from asymptomatic infection to acute schistosomiasis, or from asymptomatic infection/acute schistosomiasis into the chronic phase. Phenobarbital is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate. 25 mg/kg PO TID for 1 day (at intervals of 4-6 hr) Cysticercosis (Off-label) 50-100 mg/kg/day PO divided q8hr for 14 days . In vitro and drug interaction studies suggest praziquantel may be a CYP3A substrate, and lesinurad is a weak CYP3A inducer. If treatment with praziquantel is necessary, treatment with fosphenytoin should be discontinued 4 weeks before administration of praziquantel. Participants will receive first dose of Cesol on Day 1 in treatment period 1 followed by first dose of Biltricide on Day 8 in treatment period 2 followed by second dose of Cesol on Day 15 in treatment period 3 followed by second dose of Biltricide on Day 22 in treatment period 4. Rifampin is a strong CYP3A4 inducer and praziquantel is a CYP3A4 substrate. When praziquantel was administered two weeks after discontinuation of the strong inducer, the mean praziquantel AUC and Cmax were 23% and 35% lower, respectively, than when praziquantel was given alone. Nevirapine: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. The dosage recommended for the treatment of schistosomiasis is: 20 mg/kg bodyweight three times a day as a one day treatment, at intervals of not less than 4 hours and not more than 6 hours. Initiate adjunctive corticosteroid therapy prior to antiparasitic drugs. Oxcarbazepine: (Major) In vitro and drug interactions studies suggest that the CYP3A4 isoenzyme is the major enzyme involved in praziquantel metabolism. Use crushed or disintegrated tablets within 1 hour of mixing.Tablets are scored for cutting in half or one-fourth if dosage requires. The dosage recommended for the treatment of schistosomiasis is: 20 mg/kg bodyweight three times a day as a one day treatment, at intervals of not less than 4 hours and not more than 6 hours.